Quoin Pharmaceuticals, Ltd. (QNRX) Stock Score, Valuation & Financial Research

Quoin Pharmaceuticals, Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for QNRX

Quoin Pharmaceuticals, Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 4.10. These figures are a research snapshot, not a buy or sell recommendation.

What Quoin Pharmaceuticals, Ltd. does

Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Quoin Pharmaceuticals is a late-stage clinical specialty pharmaceutical company that generates no revenue from product sales as it is currently in the development phase. Its business model relies on raising capital through equity and debt financing to fund the research, clinical trials, and regulatory approval processes for its pipeline of therapeutic products targeting rare and orphan diseases.

Products and services

  • The company is developing a pipeline of therapeutic products for rare and orphan diseases, including QRX003 for Netherton Syndrome and other topical rapamycin-based formulations for conditions like Peeling Skin Syndrome, Ichthyosis, and various malformations.

Customer types

Patients with rare and orphan diseases; Healthcare providers and care teams.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes third-party contract research organizations to conduct clinical trials and development activities; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Commercial Partners — The company has entered into nine separate strategic commercial agreements spanning 61 countries outside of its core commercial territories of the US, Western Europe, and Japan. Source

Business strengths to evaluate

  • Proprietary topical rapamycin delivery technologies Source

Business risks and research considerations

  • Unanticipated clinical trial costs and financing requirements Source
  • Dependence on successful clinical development and regulatory approval Source

Sources: Company research source · Commercial Partners · Unanticipated clinical trial costs and financing requirements

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

QNRX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.10
Market capitalization:
8.23M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -18.76M
Free cash flow:
USD -13.54M
Cash:
USD 3.85M
Total debt:
USD 0.00
EPS:
USD -14.92

What stands out

  • Free cash flow is USD -13.54M, negative for the stored period.
  • The balance sheet shows USD 3.85M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 3.85M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for QNRX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can QNRX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is QNRX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for QNRX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of QNRX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research QNRX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.